Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.59 |
| ▸ | IKBKE | Q14164 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11546384 | 0.90 | TBK1 (0.50) | TBK1IKBKE | |
| SCHEMBL2907432 | 0.89 | TBK1 (0.56) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11357263 | 0.88 | TBK1 (0.60) | TBK1IKBKEKDM4ENPC1GAA | |
| SCHEMBL19196860 | 0.85 | TBK1 (0.80) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL2904833 | 0.81 | KDM4E (0.56) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11358711 | 0.81 | TBK1 (0.49) | TBK1IKBKEKDM4ENPC1GAA | |
| SCHEMBL11368425 | 0.80 | TBK1 (0.46) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL11364300 | 0.79 | TBK1 (0.47) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL2907889 | 0.78 | TTR (0.54) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19197555 | 0.78 | TBK1 (0.79) | TBK1IKBKEKDM4ENPC1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4143042-A | ANTIALLERGENS, BRONCHODILATOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-03-06 | — | — | US | claimed |
| EP-1968981-B1 | AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS | SUPRATEK PHARMA INC (CA) | 2010-08-18 | — | — | EP | disclosed |
| US-7772255-B2 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | SEMOV ALEXANDRE | 2009-02-12 | — | — | US | disclosed |
| US-20070135473-A1 | Method of treating tumors with azaxanthones | SUPRATEK PHARMA, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135473-A1 | Method of treating tumors with azaxanthones | S100A4, S100B, S100P | TBK1 2135/4885IKBKE 1437/4885KDM4E 1501/4885 |
| US-20090042923-A1 | Method of Treating Tumors with Azaxanthones | S100A4, S100P, S100B | TBK1 2247/4885IKBKE 1422/4885KDM4E 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.